The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | Subcutaneous daratumumab: an update on the latest MM clinical trials
Previous clinical trial investigations have established that daratumumab plus bortezomib, melphalan and prednisone, also known as dara+VMP, is significantly more effective than VMP alone in terms of response and progression-free survival in multiple myeloma (MM). Speaking from the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, provides us with an update on the feasibility and tolerability of daratumumab, and explains how the drug can now be conveniently administered as a subcutaneous infusion, as well as to elderly patients.
